Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.
We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.
We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.
Location: Israel, Center District, Rehovot
Employees: 51-200
Total raised: $61M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.01.2020 | - | $61M | - |
Mentions in press and media 3
| Date | Title | Description |
| 15.01.2020 | Emendo Biotherapeutics Raises $61 Million | NEW YORK--(BUSINESS WIRE)--Emendo Biotherapeutics, a leader in next-generation gene editing using synthetic biology to address untreatable diseases, today announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-base... |
| 15.01.2020 | Emendo raises $61M to build on Takeda-partnered gene editing platform W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Emendo Biotherapeutics has raised a $61 million series B to take forward programs based on its gene editing platform. The New York-based biotech has worked to expand the list of diseases amenable to treatment with gene editing, resulting in... |
| 15.01.2020 | Emendo raises $61M to build on Takeda-partnered gene editing platform | Emendo Biotherapeutics has raised a $61 million series B to take forward programs based on its gene editing platform. The New York-based biotech has worked to expand the list of diseases amenable to treatment with gene editing, resulting in... |